Portfolio Finder

Angiolutions

Angiolutions specializes in device-based innovation in vascular medicine. Through its latest award-winning technology, the company aims to prevent the deadly progression of small abdominal aortic aneurysms.
An abdominal aortic aneurysm is a bulging of the abdominal aorta. With a growing aneurysm diameter, the risk of fatal rupture increases. While this progressive disease affects a substantial number of patients worldwide, there is no therapy available to stop aneurysm growth. Based on latest research findings, that the founding team acquired during its academic work, Angiolutions aims to stop aneurysm progression at an early stage.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 09. Dec 2020

Bomedus

BOMEDUS GmbH is an innovative start-up company in the field of medical devices. Based on latest neurophysiological insights BOMEDUS is developing a combined platform technology that can be integrated into a wide range of consumer products.

Website: bomedus.com
HTGF-Manager: Kay G. Balster
Added to portfolio 17. Apr 2012

Capical

Capical is the world leading company for contact-free ECG-measurement via capacitive electrodes. The main application areas are drivers state monitoring for the automotive industry and contact-free cardiac monitoring solutions for medical applications.

HTGF-Manager: Kay G. Balster
Added to portfolio 27. Jul 2011

CereGate

CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.

HTGF-Manager: Tobias Faupel
Added to portfolio 06. Dec 2019

coramaze

coramaze technologies GmbH, based in Munich, Germany and founded in 2013 as a University Hospital of Essen spin-off, is engaged in developing an innovative Mitral Valve repair system - mitramaze® - for a minimally invasive transcatheter repair of mitral regurgitation (MR).

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 06. Feb 2014

CorTec

CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.

HTGF-Manager: Marco Winzer
Added to portfolio 12. Aug 2011

Cryotherapeutics

Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.

HTGF-Manager: Kay G. Balster
Added to portfolio 21. Dec 2009

HMC+

Production of chitin and chitosan-based high purity biopolymers. HMC develops new chitosan applications for the pharmaceutical industry, nanoparticles for drug delivery systems, and is a custom manufacturer of chitosan derivatives.

HTGF-Manager: Ulrike Kalapis
In portfolio 03. Jun 2008 – 23. Jun 2020

Humedics

Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.

HTGF-Manager: Dr. Bernd Goergen
Added to portfolio 28. Dec 2009

Implandata Ophthalmic Products

IOP GmbH will initiate a paradigm chance in glaucoma therapy by its products for telemetric, 24 hour monitoring of intraocular pressure, allowing personalized patient management.

HTGF-Manager: Ulrike Kalapis
Added to portfolio 19. May 2010

Inovedis

Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX implant system allows refixation of the tendon with a simplified surgical technique and is optimized for minimally invasive surgery. The technique is easy and quick to learn for the surgeon, minimizing complications due to surgical mistakes. The novel surgical principle suggests significant time and cost reductions as well as improved outcomes. Inovedis was founded in 2016. The company started operations in 2019.

HTGF-Manager: Dr. Caroline Fichtner
Added to portfolio 05. May 2021

Kumovis

The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses on the processing of high-performance polymers, which are already established in medical technology. With the Kumovis system these plastics can be processed individually, decentrally and with a high degree of design freedom. Through the integration of a unique air circuit including filter units, the technology enables a clean room environment within the build chamber. The contamination of the component with foreign particles can be avoided. As a result, the Kumovis printer can produce products such as implants cost-effectively and at the same time patient-individualized.

Lindis Blood Care

Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood collected during the operation. The product consists of a combination of an antibody and filter and serves to remove cancer cells from the blood.

HTGF-Manager: Dr. Julian Zachmann
Added to portfolio 23. Sep 2019

Mecuris

Mecuris enables the individual and custom-made production of orthopaedic aids by means of an intuitive web-based platform and subsequent manufacturing using 3D printing. This includes orthoses (e.g. for stabilising the cervical spine) and prostheses (e.g. artificial limbs), as well as equipment such as covers for below-knee prostheses. Mecuris not only provides orthopaedic clinics and medical supply stores with its innovative platform, but also with a full service package right up to delivery of the manufactured products. Design data is adjusted to a patient’s anatomy in an automated fashion based on digital patient data (CT, scanning, photos).

mediaire

mediaire GmbH was founded in 2018 in Berlin by experienced MRT and AI experts in order to support radiologists with innovative software solutions for the automatic diagnosis of MRT images. mediaire's solutions can be fully integrated into the internal IT infrastructure of radiology centers to ensure a smooth workflow and the highest possible protection of sensitive patient data. The first product md.Brain, which can be used for early detection and follow-up of neurodegenerative diseases, is already certified as a medical device and is therefore available for immediate use. Among the co-founders are two medical physicists with expertise in MRI and CI (Dr. Andreas Lemke and Dr. Jörg Döpfert), as well as two experienced scientists and specialists in radiology (Prof. Dr. med. Henrik Michaely and Prof. Dr. med. Michael Fenchel).

Website: mediaire.de
HTGF-Manager: Dr. Julian Zachmann
Added to portfolio 15. Mar 2019

MEDOVENT

Development of innovative, bioabsorbable products with a focus on medical applications.

HTGF-Manager: Kay G. Balster
In portfolio 11. Oct 2006 – 31. Oct 2018

multiBIND

multiBIND develops innovative solutions for molecular biology, healthcare and agriculture. bioDECONT® and bioCLEAN represent biocompatible disinfection and decontamination in laboratories, hospitals and agriculture.

NovaPump

NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support).
NovaPump’s catheter-based heart pump PERKAT™ can be implanted within minutes in acute situations involving acute right heart failure, cardiogenic shock or acute right heart insufficiency and offers highly efficient pulsatile heart support in combination with the existing IABP (Intra-Aortic Balloon Pump) technology as a drive.
A perspective application of PERKAT™ as a bi-ventricular assist device (bi-VAD) is also planned for the near future.

HTGF-Manager: Dr. Martin Pfister
Added to portfolio 28. Jun 2013

Pentracor

Pentracor produces a CE approved device for the therapeutic, extracorporeal removal of CRP from blood plasma of patients with acute myocardial infarction in order to decrease long-term damage. The clinical trial provides with excellent interim results.

HTGF-Manager: Dr. Bernd Goergen
Added to portfolio 03. May 2011

Photonics Healthcare (Teilexit)

Photonics Healthcare enables doctors to monitor cellular oxygen.

HTGF-Manager: Ulrike Kalapis
Added to portfolio 08. Aug 2013

Purenum

Purenum is a spin-off of the Fraunhofer-IFAM and develops biocompatible adhesives for medical use. As part of a BMBF project (GO-Bio 6 "mediNiK"), an adhesive was developed that can be used to glue together and remove previously ungrippable kidney stone fragments after lithotripsy. In addition to work on the commercialisation of the kidney stone adhesive, Purenum is also developing adhesives for other medical indications.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 16. Jul 2018

Reactive Robotics

Reactive Robotics develops adaptive and intelligent therapy robotics which automate early-mobilization in the intensive care unit. Using robotic modules that can be attached and detached on and from the patient bed, patients can be mobilized directly in their hospital bed. As compared to existing solutions, this approach supersedes the time-intensive and dangerous transfer of the patient onto a separate therapy device. The device is scheduled to become available in Europe beginning of 2018.

HTGF-Manager: Marco Winzer
Added to portfolio 31. May 2016

RIMASYS

RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education and validation with life-like fractured human specimen.

HTGF-Manager: Dr. Anke Caßing
In portfolio 04. Oct 2017 – 03. Apr 2021

Synoste

Synoste targets a disruptive change to the treatment and management of patients with bone deformities

Website: synoste.com
HTGF-Manager: Kay G. Balster
In portfolio 11. Nov 2013 – 27. May 2020

Vacis

VACIS is the leading tissue engineering company for body-own blood vessels.
The company develops in situ tissue engineered blood vessels providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovascular fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.

HTGF-Manager: Dr. Anke Caßing
Added to portfolio 31. Jul 2019

WISE

WISE Srl is a Milan- and Berlin-based company developing genuinely novel and minimally-invasive implantable leads for Neuromodulation and Neuromonitoring: highly conformable, stretchable, unbreakable and cheaper to produce.

HTGF-Manager: Kay G. Balster
Added to portfolio 05. Nov 2013